載入...
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit KRAS directly have been unsuccessful. Our previous studies showed that inhibition of cyclin-dependent kinase 5 (CDK5), reduces pancreatic cancer growth and progression, th...
Na minha lista:
發表在: | Mol Cancer Ther |
---|---|
Main Authors: | , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
2015
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497872/ https://ncbi.nlm.nih.gov/pubmed/25931518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0028 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|